Biotech Stocks with Promising Technology Analyst Coverage Amedica Corporation and Amyris, Inc.

Last Wednesday, August 17^th, Amedica Corporation (NASDAQ: AMDA), a developer of interbody implants manufactured with medical-grade silicon nitride ceramic, announced they had received a NASDAQ de-listing notice due to their share price being under $1.00. This week AMDA shares jumped from $.64 per share on Friday the 19^th to $1.32 in intraday trading on Wednesday. Read analyst report here

Amyris, Inc. (NASDAQ: AMRS) provides various alternatives to a range of petroleum-sourced products. On June 14^th of this year the company announced it had received a NASDAQ de-listing notice due to their share price remaining under $1.00. The company has until December 12^th to remedy the de-listing criterion. Read analyst report here
 
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the subject company in this report to be materially different from the statements made herein.
 
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. The subject Companies have not compensated Traders News Source for the creation or dissemination of this report. Traders News Source is the party responsible for issuing this report/release and for hosting the full report on Traders News Source website.
 
NOT FINANCIAL ADVICE
Traders News Source makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
 
NO WARRANTY OR LIABILITY ASSUMED
Traders News Source is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Traders News Source whatsoever for any direct, indirect or consequential loss arising from the use of this document. Traders News Source expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Traders News Source does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
 Traders News Source produces reports, articles, blogs, and investment newsletters covering companies listed on NYSE and NASDAQ exchanges. Traders News Source has two distinct and independent operating segments. One produces non-compensated analyst and or expert certified content generally in the form of press releases, articles and reports. The other produces compensated content, which typically consists of compensated investment newsletters, articles and reports.
 
HIGH DEGREE OF RISK
 
There is an extremely high inherent risk when investing in micro and small cap biotech securities that
have little to no revenue and are dependent upon an approval from the development of their drug
pipeline. You could lose your entire investment.
 
Source: Traders News Source
Contact: [e-mail]